JPWO2021003399A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021003399A5 JPWO2021003399A5 JP2022500008A JP2022500008A JPWO2021003399A5 JP WO2021003399 A5 JPWO2021003399 A5 JP WO2021003399A5 JP 2022500008 A JP2022500008 A JP 2022500008A JP 2022500008 A JP2022500008 A JP 2022500008A JP WO2021003399 A5 JPWO2021003399 A5 JP WO2021003399A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870644P | 2019-07-03 | 2019-07-03 | |
| US62/870,644 | 2019-07-03 | ||
| PCT/US2020/040711 WO2021003399A1 (en) | 2019-07-03 | 2020-07-02 | Anti-tissue factor antibody-drug conjugates and related methods |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022538908A JP2022538908A (ja) | 2022-09-06 |
| JPWO2021003399A5 true JPWO2021003399A5 (https=) | 2023-07-10 |
| JP2022538908A5 JP2022538908A5 (https=) | 2023-07-10 |
| JP7709636B2 JP7709636B2 (ja) | 2025-07-17 |
Family
ID=74100836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022500008A Active JP7709636B2 (ja) | 2019-07-03 | 2020-07-02 | 抗組織因子抗体－薬物コンジュゲート及び関連方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220257789A1 (https=) |
| EP (1) | EP3994150A4 (https=) |
| JP (1) | JP7709636B2 (https=) |
| KR (1) | KR20220029724A (https=) |
| CN (1) | CN114222752B (https=) |
| AR (1) | AR119346A1 (https=) |
| AU (1) | AU2020299398C9 (https=) |
| BR (1) | BR112021025720A2 (https=) |
| CA (1) | CA3141428A1 (https=) |
| CL (2) | CL2021003414A1 (https=) |
| CO (1) | CO2022001083A2 (https=) |
| CR (1) | CR20220047A (https=) |
| DO (1) | DOP2021000268A (https=) |
| EA (1) | EA202193309A1 (https=) |
| EC (1) | ECSP22007981A (https=) |
| IL (1) | IL289138A (https=) |
| MX (1) | MX2021015974A (https=) |
| PE (1) | PE20221004A1 (https=) |
| PH (1) | PH12021553289A1 (https=) |
| TW (1) | TWI879780B (https=) |
| WO (1) | WO2021003399A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3735271A4 (en) | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
| TW202342517A (zh) * | 2022-01-12 | 2023-11-01 | 美商艾康尼醫療有限責任公司 | 使用抗組織因子抗體之炎性疾病治療 |
| AU2023225240A1 (en) * | 2022-02-24 | 2024-09-05 | Evopoint Biosciences Co., Ltd. | Antibody, and drug conjugate and use thereof |
| TW202345906A (zh) * | 2022-03-09 | 2023-12-01 | 美商艾克塞里克斯公司 | 以抗組織因子抗體藥物結合物治療實體腫瘤之方法 |
| US20250276077A1 (en) * | 2022-04-05 | 2025-09-04 | Immunome, Inc. | Epha2 antibodies |
| CN116143929B (zh) * | 2023-02-03 | 2023-08-01 | 北京基科晟斯医药科技有限公司 | 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用 |
| CN116789837B (zh) * | 2023-03-24 | 2024-02-23 | 山西纳安生物科技股份有限公司 | 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用 |
| CN118772282A (zh) * | 2023-04-10 | 2024-10-15 | 复旦大学 | 靶向组织因子的纳米抗体及偶联物的制备方法和用途 |
| TW202448934A (zh) * | 2023-04-28 | 2024-12-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗tf抗體和抗tf抗體-藥物偶聯物及其醫藥用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| AU2015318556C1 (en) * | 2014-09-17 | 2021-01-07 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CN107708733B (zh) * | 2015-04-07 | 2022-11-15 | 艾利妥 | 抗分拣蛋白抗体和其使用方法 |
| EP3672990A1 (en) * | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| IL274122B2 (en) * | 2017-11-02 | 2024-09-01 | Genmab As | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| MX2020005473A (es) * | 2017-11-27 | 2020-08-27 | Purdue Pharma Lp | Anticuerpos humanizados que se dirigen al factor tisular humano. |
| EP3735271A4 (en) * | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
| TWI841554B (zh) * | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| MX2022015375A (es) * | 2020-06-29 | 2023-01-16 | Genmab As | Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer. |
-
2020
- 2020-07-02 MX MX2021015974A patent/MX2021015974A/es unknown
- 2020-07-02 CA CA3141428A patent/CA3141428A1/en active Pending
- 2020-07-02 JP JP2022500008A patent/JP7709636B2/ja active Active
- 2020-07-02 PE PE2021002191A patent/PE20221004A1/es unknown
- 2020-07-02 BR BR112021025720A patent/BR112021025720A2/pt unknown
- 2020-07-02 AU AU2020299398A patent/AU2020299398C9/en active Active
- 2020-07-02 KR KR1020227003549A patent/KR20220029724A/ko active Pending
- 2020-07-02 EP EP20835557.8A patent/EP3994150A4/en active Pending
- 2020-07-02 CN CN202080054283.1A patent/CN114222752B/zh active Active
- 2020-07-02 PH PH1/2021/553289A patent/PH12021553289A1/en unknown
- 2020-07-02 EA EA202193309A patent/EA202193309A1/ru unknown
- 2020-07-02 WO PCT/US2020/040711 patent/WO2021003399A1/en not_active Ceased
- 2020-07-02 CR CR20220047A patent/CR20220047A/es unknown
- 2020-07-02 US US17/624,541 patent/US20220257789A1/en active Pending
- 2020-07-03 TW TW109122635A patent/TWI879780B/zh active
- 2020-07-03 AR ARP200101887A patent/AR119346A1/es unknown
-
2021
- 2021-12-19 IL IL289138A patent/IL289138A/en unknown
- 2021-12-20 DO DO2021000268A patent/DOP2021000268A/es unknown
- 2021-12-20 CL CL2021003414A patent/CL2021003414A1/es unknown
-
2022
- 2022-02-01 CO CONC2022/0001083A patent/CO2022001083A2/es unknown
- 2022-02-01 EC ECSENADI20227981A patent/ECSP22007981A/es unknown
-
2024
- 2024-10-14 CL CL2024003094A patent/CL2024003094A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Samantasinghar et al. | A comprehensive review of key factors affecting the efficacy of antibody drug conjugate | |
| US20230381321A1 (en) | Camptothecin conjugates | |
| Yao et al. | Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress | |
| US20260061058A1 (en) | Biparatopic fr-alpha antibodies and immunoconjugates | |
| JP6412114B2 (ja) | 抗体薬物コンジュゲート | |
| de Goeij et al. | New developments for antibody-drug conjugate-based therapeutic approaches | |
| US20240261422A1 (en) | Anthracycline antibody conjugates | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP2011528360A5 (https=) | ||
| WO2013177481A1 (en) | Benzodiazepines and conjugates thereof | |
| JP7203729B2 (ja) | ベンゾジアゼピン誘導体の選択的スルホン化 | |
| CN107530442A (zh) | 位点特异性抗体‑药物缀合物 | |
| CN106999606A (zh) | 抗体药物偶联物 | |
| CN108093640A (zh) | 位点特异性抗体-药物缀合物 | |
| TW202214305A (zh) | 自行穩定之接合劑共軛物 | |
| CN107548306A (zh) | 位点特异性抗体‑药物缀合物 | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| JPWO2021003399A5 (https=) | ||
| US20200297863A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| JPWO2020223221A5 (https=) | ||
| JPWO2022078523A5 (https=) | ||
| AU2024210908A1 (en) | Antibody-drug conjugate and use thereof | |
| RU2832083C2 (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| RU2021130453A (ru) | Бипаратопные fr-альфа антитела и иммуноконъюгаты | |
| HK40093450A (zh) | 抗cd73抗体、抗体偶联药物及其用途 |